Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/225577 |
Resumo: | An emerging body of evidence has implicated plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though findings have not always been consistent. We systematically reviewed epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 prospective) were included. In pooled random-effects analyses of prospective studies, a comparison of the top third vs. bottom third of baseline PAI-1 values generated a RR of T2D of 1.67 (95% CI 1.28–2.18) with moderate heterogeneity (I2=38%). Additionally, of 47 cross-sectional comparisons, 34(72%) reported significantly elevated PAI-1 among diabetes cases versus controls, 2(4%) reported significantly elevated PAI-1 among controls, and 11(24%) reported null effects. Results from pooled analyses of prospective studies did not differ substantially by study design, length of follow-up, adjustment for various putative confounding factors, or study quality, and were robust to sensitivity analyses. Findings from this systematic review of the available epidemiological literature support a link between PAI-1 and T2D, independent of established diabetes risk factors. Given the moderate size of the association and heterogeneity across studies, future prospective studies are warranted. |
id |
UFRGS-2_c2e69bbe13481adf411b5e9964bba976 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/225577 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Yarmolinsky, JamesBarbieri, Natália BordinWeinmann, TobiasZiegelmann, Patricia KlarmannDuncan, Bruce BartholowSchmidt, Maria Inês2021-08-12T04:43:48Z20162045-2322http://hdl.handle.net/10183/225577001007837An emerging body of evidence has implicated plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though findings have not always been consistent. We systematically reviewed epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 prospective) were included. In pooled random-effects analyses of prospective studies, a comparison of the top third vs. bottom third of baseline PAI-1 values generated a RR of T2D of 1.67 (95% CI 1.28–2.18) with moderate heterogeneity (I2=38%). Additionally, of 47 cross-sectional comparisons, 34(72%) reported significantly elevated PAI-1 among diabetes cases versus controls, 2(4%) reported significantly elevated PAI-1 among controls, and 11(24%) reported null effects. Results from pooled analyses of prospective studies did not differ substantially by study design, length of follow-up, adjustment for various putative confounding factors, or study quality, and were robust to sensitivity analyses. Findings from this systematic review of the available epidemiological literature support a link between PAI-1 and T2D, independent of established diabetes risk factors. Given the moderate size of the association and heterogeneity across studies, future prospective studies are warranted.application/pdfengScientific Reports [recurso eletrônico]. London. Vol. 6, Artigo 17714 (2016), [13] p.Estatística médicaPlasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studiesEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001007837.pdf.txt001007837.pdf.txtExtracted Texttext/plain68564http://www.lume.ufrgs.br/bitstream/10183/225577/2/001007837.pdf.txt88413a45d11b27ba8c721c589aee47e0MD52ORIGINAL001007837.pdfTexto completo (inglês)application/pdf1074623http://www.lume.ufrgs.br/bitstream/10183/225577/1/001007837.pdfeb58c750cce4b5063096771796ed0a3dMD5110183/2255772021-08-18 04:38:50.119801oai:www.lume.ufrgs.br:10183/225577Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-08-18T07:38:50Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
title |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
spellingShingle |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies Yarmolinsky, James Estatística médica |
title_short |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
title_full |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
title_fullStr |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
title_full_unstemmed |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
title_sort |
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies |
author |
Yarmolinsky, James |
author_facet |
Yarmolinsky, James Barbieri, Natália Bordin Weinmann, Tobias Ziegelmann, Patricia Klarmann Duncan, Bruce Bartholow Schmidt, Maria Inês |
author_role |
author |
author2 |
Barbieri, Natália Bordin Weinmann, Tobias Ziegelmann, Patricia Klarmann Duncan, Bruce Bartholow Schmidt, Maria Inês |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Yarmolinsky, James Barbieri, Natália Bordin Weinmann, Tobias Ziegelmann, Patricia Klarmann Duncan, Bruce Bartholow Schmidt, Maria Inês |
dc.subject.por.fl_str_mv |
Estatística médica |
topic |
Estatística médica |
description |
An emerging body of evidence has implicated plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though findings have not always been consistent. We systematically reviewed epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 prospective) were included. In pooled random-effects analyses of prospective studies, a comparison of the top third vs. bottom third of baseline PAI-1 values generated a RR of T2D of 1.67 (95% CI 1.28–2.18) with moderate heterogeneity (I2=38%). Additionally, of 47 cross-sectional comparisons, 34(72%) reported significantly elevated PAI-1 among diabetes cases versus controls, 2(4%) reported significantly elevated PAI-1 among controls, and 11(24%) reported null effects. Results from pooled analyses of prospective studies did not differ substantially by study design, length of follow-up, adjustment for various putative confounding factors, or study quality, and were robust to sensitivity analyses. Findings from this systematic review of the available epidemiological literature support a link between PAI-1 and T2D, independent of established diabetes risk factors. Given the moderate size of the association and heterogeneity across studies, future prospective studies are warranted. |
publishDate |
2016 |
dc.date.issued.fl_str_mv |
2016 |
dc.date.accessioned.fl_str_mv |
2021-08-12T04:43:48Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/225577 |
dc.identifier.issn.pt_BR.fl_str_mv |
2045-2322 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001007837 |
identifier_str_mv |
2045-2322 001007837 |
url |
http://hdl.handle.net/10183/225577 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Scientific Reports [recurso eletrônico]. London. Vol. 6, Artigo 17714 (2016), [13] p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/225577/2/001007837.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/225577/1/001007837.pdf |
bitstream.checksum.fl_str_mv |
88413a45d11b27ba8c721c589aee47e0 eb58c750cce4b5063096771796ed0a3d |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225032154742784 |